MarketPulse

CRISPR gene therapy

2 articles
Investing.comInvesting.com··Chris Markoch

CRISPR Therapeutics Rallies on Pipeline Momentum Despite Quarterly Losses

CRISPR stock rallied 12% on pipeline momentum despite quarterly losses and minimal revenue, buoyed by cash reserves and CTX611 candidate progress.
VRTXCRSPrevenue recognitionbiotech pipeline
BenzingaBenzinga··Vandana Singh

CRISPR Therapeutics Posts Strong Gene Therapy Gains as Casgevy Adoption Accelerates

CRISPR Therapeutics reports strong Q4 results with Casgevy gene therapy generating $116M revenue and 147 patient initiations, signaling accelerating adoption and market confidence.
LLYVRTXREGNCRSPARWRsickle cell diseaseCasgevy